A clinical trial into the experimental Alzheimer's medication semagacestat ended this week when the drug was found to increase symptoms of memory loss, rather than decrease them. Drugmaker Eli Lilly says the most disappointing news is that their drug is one of many in development that blocks beta amyloid in the brain, and those other experimental medications may also worsen dementia symptoms. Experts say this is a blow to researchers who have believed that blocking the protein holds the key for...
Read moreThe American Academy of Neurology 60th Annual Meeting brought news of a new Alzheimer's drug called Dimebon. The drug just made it through... Read more »
When an “AARP Bulletin” arrived in my e-mailbox, I literally caught my breath at the headline, “Closing In on Alzheimer’s: Finally,... Read more »
We’ve been waiting for details and now they are here. The Obama administration plan to end Alzheimer’s disease by the year 2025 was... Read more »
Disheartening news about currently available Alzheimer's drugs was published on Reuters.com this week. In an article titled "US review... Read more »
While it's well known that the drugs available now for people with Alzheimer's disease, namely donepezil (Aricept), rivastigmine... Read more »
Some researchers say the problem with current Alzheimer's drugs is that they treat the symptoms, not the cause of the disease. A few new drug classes... Read more »
New guidelines based on 96 different studies suggest that none of the five available Alzheimer's drugs work better than any of the others, and what... Read more »
Patients who are currently taking an Alzheimer's medication such as Aricept should consult a doctor before taking the Chinese herb huperzine A.... Read more »
A Russian antihistamine called dimebon has shown very promising results in treating Alzheimer's disease, but experts say the mystery is that the drug... Read more »
A new study shows that THC, the key compound in marijuana, blocks the formation of brain-clogging plaques better than current Alzheimer's drugs do.... Read more »